IQVIA (NYSE:IQV) Shares Gap Down – Here’s What Happened

IQVIA Holdings Inc. (NYSE:IQVGet Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $216.04, but opened at $200.30. IQVIA shares last traded at $202.71, with a volume of 621,098 shares traded.

Analysts Set New Price Targets

IQV has been the subject of several analyst reports. Redburn Atlantic initiated coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Barclays decreased their price objective on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Truist Financial decreased their price objective on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Finally, Morgan Stanley raised their price objective on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $267.27.

Check Out Our Latest Stock Report on IQVIA

IQVIA Trading Down 2.6 %

The company has a market capitalization of $38.35 billion, a PE ratio of 28.06, a price-to-earnings-growth ratio of 2.09 and a beta of 1.49. The company’s fifty day moving average is $235.88 and its 200-day moving average is $230.06. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently bought and sold shares of IQV. First Foundation Advisors raised its stake in IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after purchasing an additional 43 shares during the period. Team Hewins LLC raised its stake in IQVIA by 5.0% during the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock worth $246,000 after purchasing an additional 46 shares during the period. Invera Wealth Advisors LLC raised its stake in IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after purchasing an additional 46 shares during the period. Covestor Ltd raised its stake in shares of IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 48 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its stake in shares of IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after acquiring an additional 48 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.